In Vitro Antiviral Testing and Validation
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract involves conducting in vitro assays to assess the antiviral activity, cytotoxicity, and selectivity of small molecules against live Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV) within high-containment laboratory settings. This work is critical for validating the effectiveness and safety of potential antiviral compounds targeting these high-risk pathogens. Issued by the Department of Health and Human Services under the ASPR Administration for Strategic Preparedness and Response, the subcontract seeks qualified entities to perform these specialized assays. The opportunity was posted on May 19, 2026, with a response deadline of July 17, 2026. The contract is designated under NAICS code 541611, reflecting management and scientific services, and requires adherence to strict biosecurity protocols given the nature of the viruses involved.
General Info
Agency
NAICS
Place of Performance
DCSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
